Search
Close this search box.

Science spotlight: Moonlight’s enhanced T cells; plus a HUNK inhibitor and more

ARTICLE | Discovery & Translation

BioCentury’s roundup of translational innovations

By Danielle Golovin, Sernior Biopharma Analyst

February 10, 2024 1:22 AM UTC

Moonlight Bio Inc. has devised a new screening technique that can make T cell therapies more effective by identifying naturally occurring mutations that increase endogenous T cell fitness.

The authors, including researchers from Northwestern University and  University of California San Francisco, found that a gene fusion between CARD11 and PIK3R3 increased AP-1 and NF-κB signaling, IL-2 production and tumor killing in vitro and in vivo. “Notably, this perturbation linking portions of two genes together would not have been identified by previous screening approaches,” said the authors of the Nature article